| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 80.70B | — |
| Operating expense | — | — |
| Net income | 4.43B | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, RDY returned -15.0% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | -12.2% |
| 1 year | -15.0% |
| 5 years | +0.0% |
| 10 years | +46.9% |
| All-time high | $16.69 (Aug 2024) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in RDY would be worth today ›Yes. Dr. Reddy's Laboratories Limited paid 1 dividend over the past 12 months. The most recent was $0.08 per share on Jul 24, 2026. The dividend yield is 0.68%.
Dr. Reddy's Laboratories Limited stock trades on NYSE under the ticker symbol RDY.
Dr. Reddy's Laboratories Limited is part of the Healthcare sector.
Dr. Reddy's Laboratories Limited has a market cap of 10.20B USD, based on the latest quote.
Dr. Reddy's Laboratories Limited is scheduled to report earnings on Oct 22, 2026.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.